Every year in America, nearly 25,000 people are diagnosed with brain cancer. Most of them -- more than 18,000 -- are ...

The global traumatic brain injury (TBI) treatment market is undergoing a significant transformation, fueled by rising global incidence rates, expanding awareness about brain health, and accelerating ...

If you never heard about Andrigolitis before, you’re not alone — it’s one of those bizarre health topics that suddenly pop up in conversations and online ...

One of the most alarming facts about 24ot1jxa is its effect on breathing. When inhaled, even in small amounts, it irritates the lungs and airways. This could lead to chronic coughing, wheezing, or ...

Skin grafts genetically engineered from a patient’s own cells can heal persistent wounds in people with an extremely painful ...

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

How one of the oldest components of the human immune system can trigger a mysterious and little-understood syndrome.

LAS VEGAS, June 12, 2025 /PRNewswire/ -- DelveInsight's Cancer Pain Market Insights report includes a comprehensive understanding of current treatment practices, cancer pain emerging drugs, market ...

The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. • Delgocitinib ...

LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP) Provided by Business Wire Jun 3, 2025, 12:00:00 AM ...

The majority of effusions were mild to moderate in severity and resolved in a median of 33 days among patients in the pretreated group. The percentage of participants with treatment related knee ...